Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
about
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire.Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibThe war on cancer: a report from the front linesABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitorsIn search of CML stem cells' deadly weakness.Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008.Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia.Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients.Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML.Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes.Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.Pregnancy in patients with chronic myeloid leukemia treated with imatinib.Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.
P2860
Q33226589-D2FA6F5D-CA67-4AE8-BB68-23B2997A9847Q33394772-AF5952CF-7AB1-429A-AFBC-63F91CDCABBEQ33561232-FA01E508-6B54-4614-9DC1-56F673A897C5Q33750753-AE0939DF-BFF8-4AFC-801F-03EE0B2F6C86Q34123610-2C36A382-F53E-4146-A6E8-5C81A106965AQ35073857-319B729B-9A87-4D17-A2DF-A1D5A4701ACBQ35103643-0605B28C-1DBB-43CC-963B-EA92C5262E34Q35171274-D0E7937B-F8C9-46C9-857D-5FF7C018CF90Q35300745-B02EDC70-A5B8-4AB2-8D72-A5ABFD705ADBQ35904266-0C596DF8-2697-4C50-95E7-B446BD1D368AQ35949910-52D85201-C5A7-48BB-8F6B-FE851CEBEECBQ37109841-979713E2-F04B-4B2C-B211-8F4769B0EB5EQ37361209-AF6A916C-9E4A-4951-9070-1578A7B671D3Q37849628-C512A338-DC87-494C-AC19-2821C83A2D9DQ37877650-356F8DCC-A4D4-4C6E-922F-344BF0E73763Q37918304-A75742C8-AC32-41FC-90C6-0E4583DC7545Q38154622-CE07530E-0F8D-4B50-92EC-45EAD0797142Q38846325-DFC6E4CE-9444-4C1A-B6E1-765F44DF0A1CQ39694428-9E7A21D9-954B-4FD7-9AAF-D488CBC82F87Q39971301-6173083F-4A39-4F2E-BD51-0667A27EB610Q40486959-8F098B8F-4D0A-494E-A2A5-0853DC1A4759Q41892288-E1B3D336-CD5D-437A-845C-81A4E756B6D0Q41925673-5F682316-8C5E-4E3B-9E58-6E59F812FAC4Q42137176-B71A5F9E-04A6-4B45-8932-0F36F3E8F4E4Q43168908-B6E090F4-79B8-4B88-B21D-321F98943E53Q43838655-04F89205-6C97-4E6F-A049-E84DFFB033F5Q43901048-5E48F5A5-37CC-437C-B9E2-09424A849488Q44511391-8B30B74B-ED83-41E4-B064-D4E9F7F935B6Q44605528-95279550-E425-4390-B984-DCAFDC036F35Q44632359-BEE88BE4-93B0-44D4-8A02-92EF257226E9Q44703351-766734AD-AC72-437E-8FFB-745298FE54C5Q44791839-A4F22D50-506B-4C25-B712-F568BBCEC828Q44908700-45039318-A43D-4655-BB3E-09D186C74E11Q45147334-A5A08C30-C724-49EF-BBB6-D0872D7145A4Q45197239-4F72269A-4D7D-4706-9F06-8ADEA5B96CD3Q46735722-50B16358-15C6-4ABF-AB17-D3A11DCBEFBFQ46860346-41163F96-7628-4661-A98E-412EA04CB1F0Q49303056-CF23EB7E-847D-4F65-A8CC-6C5DCABE5DCA
P2860
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@en
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@nl
type
label
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@en
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@nl
prefLabel
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@en
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@nl
P2093
P50
P1433
P1476
Imatinib mesylate therapy in n ...... d major cytogenetic responses.
@en
P2093
Deborah Thomas
Kathy Bochinski
Laurie Letvak
Moshe Talpaz
Ralph Arlinghaus
P304
P356
10.1182/BLOOD-2002-02-0545
P407
P50
P577
2002-08-29T00:00:00Z